Patient and Donor Characteristics
| . | PBSCT . | BMT . | . |
|---|---|---|---|
| No. of patients | 25 | 31 | |
| Dates of transplant | 6/96-11/97 | 3/93-5/96 | |
| Age in yr, median (range) | |||
| Patient | 30 (17-49) | 31 (15-42) | NS |
| Donor | 26 (17-44) | 25 (14-48) | NS |
| Gender-150 | |||
| Patient female | 8 (32%) | 10 (32.3%) | NS |
| Donor female | 10 (40%) | 11 (35.5%) | NS |
| Donor multiparous | 3 (30%) | 5 (45.5%) | NS |
| Sex mismatch | 7 (28%) | 11 (35.5%) | NS |
| CMV serology-150 | |||
| Patient and donor positive | 24 (96%) | 25 (80.7%) | NS |
| Diagnosis-150 | NS | ||
| Chronic myeloid leukemia | 14 (56%) | 13 (42%) | |
| Acute myeloid leukemia | 5 (20%) | 11 (35.5%) | |
| Acute lymphoid leukemia | 1 (4%) | 5 (16%) | |
| Others-151 | 5 (20%) | 2 (6.5%) | |
| Advanced hematological malignancy | 5 (20%) | 11 (35.5%) | NS |
| Preparative regimens-150 | NS | ||
| Cy/TBI | 4 (16%) | 9 (29%) | |
| Bu/Cy ± VP-16 | 20 (80%) | 21 (67.7%) | |
| Others | 1 (4%) | 1 (3.2%) |
| . | PBSCT . | BMT . | . |
|---|---|---|---|
| No. of patients | 25 | 31 | |
| Dates of transplant | 6/96-11/97 | 3/93-5/96 | |
| Age in yr, median (range) | |||
| Patient | 30 (17-49) | 31 (15-42) | NS |
| Donor | 26 (17-44) | 25 (14-48) | NS |
| Gender-150 | |||
| Patient female | 8 (32%) | 10 (32.3%) | NS |
| Donor female | 10 (40%) | 11 (35.5%) | NS |
| Donor multiparous | 3 (30%) | 5 (45.5%) | NS |
| Sex mismatch | 7 (28%) | 11 (35.5%) | NS |
| CMV serology-150 | |||
| Patient and donor positive | 24 (96%) | 25 (80.7%) | NS |
| Diagnosis-150 | NS | ||
| Chronic myeloid leukemia | 14 (56%) | 13 (42%) | |
| Acute myeloid leukemia | 5 (20%) | 11 (35.5%) | |
| Acute lymphoid leukemia | 1 (4%) | 5 (16%) | |
| Others-151 | 5 (20%) | 2 (6.5%) | |
| Advanced hematological malignancy | 5 (20%) | 11 (35.5%) | NS |
| Preparative regimens-150 | NS | ||
| Cy/TBI | 4 (16%) | 9 (29%) | |
| Bu/Cy ± VP-16 | 20 (80%) | 21 (67.7%) | |
| Others | 1 (4%) | 1 (3.2%) |
Abbreviations: NS, not significant; Cy/TBI, cyclophosphamide (120 mg/kg) and total body irradiation (12 Gy); Bu/Cy ± VP-16, Busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) with (5 patients) or without (36 patients) etoposide (30 mg/kg).
No of patients (% of patients).
Multiple myeloma: 4 patients; aplastic anemia, 1 patient; paroxysmal nocturnal hemoglobinuria, 1 patient; myelodysplastic syndrome, 1 patient.